palmitoylethanolamide.com.au
HomeResearchNilesh 2023

Exploring the Protective Effect against 7,12-Dimethylbenz[a]anthracene-Induced Breast Tumors of Palmitoylethanolamide

Nilesh Rai, Vikas Kailashiya, Vibhav Gautam. ACS Pharmacol Transl Sci. 2023 Dec 1;7(1):97-109.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumours
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Tumour area and volume by photoacoustic imaging, tumour oxygenation, liver and kidney histopathology, blood glucose and lactate dehydrogenase, oxidative stress markers, and apoptosis-related gene expression (BAX, P53, BCL-XL, CASPASE-8, CASPASE-9) and Caspase-3 activity

What the authors reported

Palmitoylethanolamide reduced tumour area and volume, increased average oxygen saturation and decreased total haemoglobin (indicating reduced hypoxia-driven blood vessel growth), and reduced DMBA-driven liver and kidney toxicity on histopathology. It lowered blood glucose and lactate dehydrogenase, reduced nitric oxide and malondialdehyde, increased glutathione, and altered apoptosis-related gene expression and Caspase-3 activity.

Limits of this study

A rat model of chemically induced breast tumours; it cannot show effect in people with breast cancer. The authors declare no competing financial interests.

Source

PubMed 38230286 · doi:10.1021/acsptsci.3c00188

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.